Misleading guidelines for the diagnosis and management of hypertension
Autor(a) principal: | |
---|---|
Data de Publicação: | 2014 |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Clinical and Biomedical Research |
Texto Completo: | https://seer.ufrgs.br/index.php/hcpa/article/view/49084 |
Resumo: | International guidelines for the diagnosis and management of hypertension were recently released [1,2]. A historical trend of lowering the blood pressure (BP) thresholds to diagnose hypertension in high risk individuals was unexpectedly reversed. BP targets for the treatment were modified accordingly. Therefore some individuals who were hypertensive before are now normotensive. Other guidelines still recommend the previous diagnostic limits and goals of treatment [3-5], resulting that an individual may be hypertensive in some countries and normotensive in others. The guidelines are more homogeneous in the recommendations for treatment, particularly in regard to the liberal options of drugs to starting the treatment. Unfortunately, in my view, this liberal view includes drugs without unbiased evidences of effectiveness, such as Angiotensin Receptor Blockers (ARB). In this point of view, I discuss the reasons and misconceptions in the establishment of diagnostic thresholds and the shortcomings in the recommendations of antihypertensive drugs. |
id |
UFRGS-20_2617222555bbfedcaf64f40a45fe9fbc |
---|---|
oai_identifier_str |
oai:seer.ufrgs.br:article/49084 |
network_acronym_str |
UFRGS-20 |
network_name_str |
Clinical and Biomedical Research |
repository_id_str |
|
spelling |
Misleading guidelines for the diagnosis and management of hypertensionHipertensionGuidelinesDiabetesHipertensionInternational guidelines for the diagnosis and management of hypertension were recently released [1,2]. A historical trend of lowering the blood pressure (BP) thresholds to diagnose hypertension in high risk individuals was unexpectedly reversed. BP targets for the treatment were modified accordingly. Therefore some individuals who were hypertensive before are now normotensive. Other guidelines still recommend the previous diagnostic limits and goals of treatment [3-5], resulting that an individual may be hypertensive in some countries and normotensive in others. The guidelines are more homogeneous in the recommendations for treatment, particularly in regard to the liberal options of drugs to starting the treatment. Unfortunately, in my view, this liberal view includes drugs without unbiased evidences of effectiveness, such as Angiotensin Receptor Blockers (ARB). In this point of view, I discuss the reasons and misconceptions in the establishment of diagnostic thresholds and the shortcomings in the recommendations of antihypertensive drugs.HCPA/FAMED/UFRGS2014-10-27info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionPeer-reviewed Article"A Convite dos Editoresapplication/pdfhttps://seer.ufrgs.br/index.php/hcpa/article/view/49084Clinical & Biomedical Research; Vol. 34 No. 3 (2014): Clinical and Biomedical ResearchClinical and Biomedical Research; v. 34 n. 3 (2014): Clinical and Biomedical Research2357-9730reponame:Clinical and Biomedical Researchinstname:Universidade Federal do Rio Grande do Sul (UFRGS)instacron:UFRGSenghttps://seer.ufrgs.br/index.php/hcpa/article/view/49084/31845Fuchs, Flávio Danniinfo:eu-repo/semantics/openAccess2024-01-19T13:30:54Zoai:seer.ufrgs.br:article/49084Revistahttps://www.seer.ufrgs.br/index.php/hcpaPUBhttps://seer.ufrgs.br/index.php/hcpa/oai||cbr@hcpa.edu.br2357-97302357-9730opendoar:2024-01-19T13:30:54Clinical and Biomedical Research - Universidade Federal do Rio Grande do Sul (UFRGS)false |
dc.title.none.fl_str_mv |
Misleading guidelines for the diagnosis and management of hypertension |
title |
Misleading guidelines for the diagnosis and management of hypertension |
spellingShingle |
Misleading guidelines for the diagnosis and management of hypertension Fuchs, Flávio Danni Hipertension Guidelines Diabetes Hipertension |
title_short |
Misleading guidelines for the diagnosis and management of hypertension |
title_full |
Misleading guidelines for the diagnosis and management of hypertension |
title_fullStr |
Misleading guidelines for the diagnosis and management of hypertension |
title_full_unstemmed |
Misleading guidelines for the diagnosis and management of hypertension |
title_sort |
Misleading guidelines for the diagnosis and management of hypertension |
author |
Fuchs, Flávio Danni |
author_facet |
Fuchs, Flávio Danni |
author_role |
author |
dc.contributor.author.fl_str_mv |
Fuchs, Flávio Danni |
dc.subject.por.fl_str_mv |
Hipertension Guidelines Diabetes Hipertension |
topic |
Hipertension Guidelines Diabetes Hipertension |
description |
International guidelines for the diagnosis and management of hypertension were recently released [1,2]. A historical trend of lowering the blood pressure (BP) thresholds to diagnose hypertension in high risk individuals was unexpectedly reversed. BP targets for the treatment were modified accordingly. Therefore some individuals who were hypertensive before are now normotensive. Other guidelines still recommend the previous diagnostic limits and goals of treatment [3-5], resulting that an individual may be hypertensive in some countries and normotensive in others. The guidelines are more homogeneous in the recommendations for treatment, particularly in regard to the liberal options of drugs to starting the treatment. Unfortunately, in my view, this liberal view includes drugs without unbiased evidences of effectiveness, such as Angiotensin Receptor Blockers (ARB). In this point of view, I discuss the reasons and misconceptions in the establishment of diagnostic thresholds and the shortcomings in the recommendations of antihypertensive drugs. |
publishDate |
2014 |
dc.date.none.fl_str_mv |
2014-10-27 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Peer-reviewed Article" A Convite dos Editores |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://seer.ufrgs.br/index.php/hcpa/article/view/49084 |
url |
https://seer.ufrgs.br/index.php/hcpa/article/view/49084 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
https://seer.ufrgs.br/index.php/hcpa/article/view/49084/31845 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
HCPA/FAMED/UFRGS |
publisher.none.fl_str_mv |
HCPA/FAMED/UFRGS |
dc.source.none.fl_str_mv |
Clinical & Biomedical Research; Vol. 34 No. 3 (2014): Clinical and Biomedical Research Clinical and Biomedical Research; v. 34 n. 3 (2014): Clinical and Biomedical Research 2357-9730 reponame:Clinical and Biomedical Research instname:Universidade Federal do Rio Grande do Sul (UFRGS) instacron:UFRGS |
instname_str |
Universidade Federal do Rio Grande do Sul (UFRGS) |
instacron_str |
UFRGS |
institution |
UFRGS |
reponame_str |
Clinical and Biomedical Research |
collection |
Clinical and Biomedical Research |
repository.name.fl_str_mv |
Clinical and Biomedical Research - Universidade Federal do Rio Grande do Sul (UFRGS) |
repository.mail.fl_str_mv |
||cbr@hcpa.edu.br |
_version_ |
1799767053663469568 |